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Abstract
The single nucleotide polymorphism (SNP) rs835487 is associated with hip osteoarthritis
(OA) at the genome-wide significance level and is located within CHST11, which codes for
carbohydrate sulfotransferase 11. This enzyme post-translationally modifies proteoglycan
prior to its deposition in the cartilage extracellular matrix. Using bioinformatics and experi-
mental analyses, our aims were to characterise the rs835487 association signal and to
identify the causal functional variant/s. Database searches revealed that rs835487 resides
within a linkage disequilibrium (LD) block of only 2.7 kb and is in LD (r2 0.8) with six other
SNPs. These are all located within intron 2 of CHST11, in a region that has predicted
enhancer activity and which shows a high degree of conservation in primates. Luciferase
reporter assays revealed that of the seven SNPs, rs835487 and rs835488, which have a
pairwise r2 of 0.962, are the top functional candidates; the haplotype composed of the OA-
risk conferring G allele of rs835487 and the corresponding T allele of rs835488 (the G-T
haplotype) demonstrated significantly different enhancer activity relative to the haplotype
composed of the non-risk A allele of rs835487 and the corresponding C allele of rs835488
(the A-C haplotype) (p < 0.001). Electrophoretic mobility shift assays and supershifts identi-
fied several transcription factors that bind more strongly to the risk-conferring G and T
alleles of the two SNPs, including SP1, SP3, YY1 and SUB1. CHST11 was found to be
upregulated in OA versus non-OA cartilage (p < 0.001) and was expressed dynamically dur-
ing chondrogenesis. Its expression in adult cartilage did not however correlate with
rs835487 genotype. Our data demonstrate that the OA susceptibility is mediated by differ-
ential protein binding to the alleles of rs835487 and rs835488, which are located within an
enhancer whose target may be CHST11 during chondrogenesis or an alternative gene.
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Introduction
Osteoarthritis (OA) is a common disease of older individuals that is characterized by the focal
loss of articular cartilage [1]. This loss usually occurs gradually over many years and typically
results in chronic pain and severely impaired joint function by the sixth or seventh decade of
life. There is accumulating evidence of increased mortality associated with the disease, which is
the result of secondary cardiovascular events arising from lower patient activity [2]. Other joint
tissues also show OA-associated changes, but alteration to normal cartilage function is pivotal
[3].
OA is polygenic and unlike many other common arthritic diseases, there are no OA risk-
conferring loci of large singular impact [4]. A number of genome-wide and candidate-gene
based studies have reported OA association signals that exceed or are close to the genome-wide
significance threshold (reviewed in [5]). Many of these signals demonstrate association only in
a particular joint type; for example, hips but not knees. Stratification by joint has therefore
proven essential in identifying OA association signals and highlights that, at the genetic level,
OA aetiology is not uniform across the skeleton.
The most powerful OA genome-wide association scan (GWAS) so far performed is the
arcOGEN study, which identified five signals at the genome-wide significance threshold and
three just below [6]. These signals were detected following the direct typing and imputation
of approximately 1.4 million autosomal single nucleotide polymorphisms (SNPs). Whilst
several of the arcOGEN signals encompass genes lacking a prior known role in joint tissue
biology, some do and one that fits into this category is on chromosome 12q23 and marked by
rs835487. This SNP is associated with hip OA in males and females at the genome-wide sig-
nificance level, with a p-value of 1.64 x 10−8. It is located within intron 2 of the carbohydrate
sulfotransferase 11 gene CHST11, which encodes an enzyme that catalyses the transfer of sul-
fate groups to chondroitin to form chondroitin-4-sulfate. This is a major component of gly-
cosaminoglycan (GAG) chains, which bind to a core protein in the cartilage extracellular
matrix to form proteoglycans that can modulate the access of growth factors to the cartilage
chondrocyte cells [7].
Following the mapping of a susceptibility locus, it is important to determine the molecu-
lar mechanism linking genetic variation with disease risk. One step in the characterisation
of the signal is the identification of the causal variant. In a genomic region where the associ-
ated variant is in high (r2 > 0.8) to perfect (r2 = 1) linkage disequilibrium (LD) with other
SNPs, this requires direct functional analysis of these correlating SNPs using relevant in sil-
ico and in vitro assays. The rs835487 association signal does not correlate with any non-
synonymous SNPs, which suggests that the functional effect of this OA signal is on gene
expression rather than via an amino acid substitution. There are several published examples
in OA of risk-conferring SNPs whose effects are mediated by modulating gene expression,
including the GDF5 SNP rs143383, the DIO2 SNP rs225014, and the ALDH1A2 SNP
rs3204689 [8–11].
We therefore hypothesised that the 12q23 OA association signal acts by modulating gene
expression and we set out to determine if this was the case by functionally investigating
rs835487 and the SNPs in LD with it. We employed bioinformatics analyses and a range of
experimental techniques to determine which, if any, of the SNPs modulated gene expression at
the allelic level, including luciferase reporter assays, electrophoretic mobility shift assays, super-
shifts and allelic expression imbalance studies. In so doing we examined a number of relevant
cell types and tissue, namely transformed cell lines, mesenchymal stem cells undergoing chon-
drogenic differentiation, and cartilage from OA patients.
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Materials and Methods
Identification of SNPs in LD with rs835487
SNPs with an r2 of over 0.8 with the OA marker SNP rs835487 in the European population
(EUR; similar to the individuals used in the arcOGEN study) were identified using the LDlink
bioinformatics tool (http://analysistools.nci.nih.gov/LDlink/; [12]), which uses genotyping data
from Phase 3 of the 1000 Genomes Project [13]. The EUR population is composed of Utah res-
idents of northern and western European ancestry (CEU; n = 99), British people from England
and Scotland (GBR; n = 91), Finnish individuals (FIN; n = 99), the Iberian population in Spain
(IBS; n = 107) and individuals from Toscani in Italy (TSI; n = 107). The major alleles and
minor OA-risk alleles for each SNP were identified using dbSNP (http://www.ncbi.nlm.nih.
gov/SNP/) and the probabilistic identification of causal SNPs (PICS) scores, which serve to
rank SNPs at a given locus as a means of identifying the most likely causal SNP, were calculated
using the PICS bioinformatics tool (https://pubs.broadinstitute.org/pubs/finemapping/pics.
php; [14]).
Identification of Sequences Homologous to the Enhancer in Non-Human
Mammals
The 2.7 kb genomic region encompassing the human enhancer region was used to interrogate
the genomes of other mammals using the UCSC BLAT software (http://genome.ucsc.edu/cgi-
bin/hgBlat). In species that had homology to the human enhancer region within intron 2 of the
orthologous CHST11 gene, the homologous regions were aligned to the entire human enhancer
sequence as well as to the regions immediately surrounding the seven SNPs individually using
the ClustalWMultiple Sequence Alignment Tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
The UCSC LiftOver tool was used to map the Chst11 chondrogenic enhancer regions identified
by Ohba et al. [15] and Liu and Lefebvre [16] from rat assembly RGSC 5.0/rn5 and mouse
assembly NCBI37/mm9 to the human GRCh37/hg19 assembly respectively. Regions of nucleo-
tide conservation between the rodent and human sequences were identified using the NCBI
blastn sequence alignment tool that is optimised for ‘somewhat similar sequences’.
Cloning of pGL3-Promoter Luciferase Reporter Plasmids
The regions chromosome 12:105059890–105061288 (containing the rs835486, rs835487 and
rs835488 SNPs), chromosome 12:105062129–105063197 (encompassing the rs835490, rs835491,
rs835492 and rs835493 SNPs), chromosome 12:105059891–105060550 (rs835486 only), chromo-
some 12:105060261–105060975 (rs835487 only) and chromosome 12:105060784–105061471
(rs835488 only) were amplified from heterozygous genomic DNA and cloned into the pGL3-Pro-
moter vector (Promega) upstream of the SV40 Promoter. Two plasmids were created for each
region, one with the major haplotype or allele and one with the minor OA-risk haplotype or allele.
The different haplotype combinations of the rs835486-rs835487-rs835488 vector were created by
site-directed mutagenesis of the AAC haplotype using the Quikchange II Site-Directed Mutagene-
sis kit (Agilent) according to the manufacturer’s instructions. Sanger sequencing confirmed the
sequence and haplotype/genotype of each vector, and the DNA was then purified using the Pure-
Yield PlasmidMaxiprep System (Promega). Primer sequences are listed in S1 Table.
Transfection of Cell Lines
SW1353 human chondrosarcoma cells (ATCC) were seeded at a density of 1.75 x 104 cells per
well in a 48-well plate 24 hours prior to transfection. MDA-MB-231 human adenocarcinoma
cells (ATCC) were seeded at a density of 2.5 x 104 cells per well in a 48-well plate 48 hours
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prior to transfection. SW1353 and MDA-MB-231 cells were co-transfected with 500 ng of the
appropriate pGL3-promoter vector and 30 ng of pRL-TK Renilla control vector (Promega)
using TurboFect transfection reagent (Thermo Scientific). After 24 hours, cells were lysed and
luciferase and Renilla activity measured using the Dual Luciferase Assay System (Promega)
according to the manufacturers’ protocol. For each construct, six wells were transfected and at
least six independent experiments performed per cell line. The luciferase/renilla ratio of each
construct was normalised to the empty pGL3-promoter vector, which was given a ratio of 1.
The significance of expression differences were assessed using a Mann-Whitney U test.
Electrophoretic Mobility Shift Assays (EMSAs)
Nuclear proteins were extracted from SW1353 cells and MDA-MB-231 cells and quantified
as described previously [17]. Single-stranded DY-682 labelled oligonucleotides were synthe-
sised (Eurofins MWG Operons), annealed to generate double-stranded probes and diluted to
100 fmol/μl. Binding reactions containing 5 μg of nuclear protein and 200 fmol of probe were
performed using the Odyssey EMSA Buffer kit (Licor Biosciences) as previously described
[18], with the addition of 0.4% NP40 and 2.5% glycerol to the rs835487 binding reactions.
Samples were electrophoresed through a 5% (w/v) polyacrylamide gel and visualised as in
Reynard et al. 2014 [18]. Transcription factors predicted to bind over the rs845487 or
rs835488 SNPs were identified using MatInspector, PROMO, TESS and TF Search online
databases [19,20]. For competition assays, unlabelled competitors identical to the probes or
containing the consensus sequence of transcription factors predicted to bind over the SNP
were added to the binding reaction in excess (10-, 25-, 50-, and 100-fold for competitors
identical to the probes; 1-, 2.5-, 5- and 10-fold for SP1/SP3 competitor to the rs835487
EMSA; 5-, 10-, 25- and 50-fold for SP1/SP3 competitor to the rs835488 EMSA). For super-
shift assays, 2 μg of rabbit polyclonal antibodies against various transcription factors includ-
ing anti-SP1 (Santa Cruz Biotechnology; sc-59 X), anti-SP3 (sc-644 X), anti-SUB1 (sc-48778
X), and anti-YY1 rabbit (sc-281 X) were added to the binding reaction, with anti-PAX6 poly-
clonal antibody being used as an IgG control. The probe and SP1/SP3 consensus competitor
sequences are listed in S1 Table.
Ethics Statement, Cartilage Collection and Nucleic Acid Extraction
The Newcastle and North Tyneside Research Ethics Committee granted ethical approval for
the collection of cartilage from patients undergoing hip or knee replacement for primary OA,
or hip replacement resulting from a neck of femur (NOF) fracture (REC reference number 14/
NE/1212). Each donor provided informed consent. The project was discussed with the donor
verbally by a trained research nurse and if the donor agreed to participate written consent was
then taken. This consent procedure was approved by the ethics committee and the written con-
sent was then filed by the consenting nurse. OA status was confirmed using pre-operative rec-
ords and all OA patients had full thickness cartilage lesions. For all patients, macroscopically
normal articular cartilage was collected [21,22]. For the OA patients, cartilage was collected
distal to the OA lesion and these patients were screened to exclude all cases of skeletal or devel-
opmental dysplasia, inflammatory arthritis and post-traumatic arthritis. Cartilage samples
were collected within four hours of surgery, snap-frozen in liquid nitrogen and stored at -80°C
until nucleic acid extraction. The frozen tissue was ground and RNA and DNA extracted using
the Omega EZNA Total DNA/RNA isolation kit (R6731-02; Omega Bio-Tek), as previously
described [21].
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Gene Expression, Genotyping and AEI Analysis
One microgram of total RNA was reverse transcribed using the SuperScript First-Strand Syn-
thesis System (Invitrogen), and the cDNA diluted 1:20 in DEPC water. CHST11 expression was
assessed by quantitative real-time RT-PCR (qRT-PCR), with three PCR replicates performed
per sample. mRNA expression levels were normalised to 18s, GAPDH andHPRT1 housekeep-
ing genes using the calculation 2^-ΔCt. The rs835487 and rs2463018 SNPs were genotyped by
restriction fragment length polymorphism (RFLP) assays using 20 ng of DNA. Allelic expres-
sion imbalance (AEI) analysis was assessed by pyrosequencing [23] and was performed on car-
tilage DNA and mRNA from individuals heterozygous for the rs2463018 SNP present in the
3ʹUTR of CHST11. Three DNA and cDNA replicates were performed per sample and the
mRNA allelic ratio normalised to the DNA ratio (representing the 1:1 ratio between alleles) for
the same sample. The qRT-PCR, RFLP and pyrosequencing primer sequences are listed in S1
Table.
Chondrogenic Differentiation of MSCs
Human iliac crest-derived mesenchymal stem cells (MSCs) from three donors aged 22–24 years
(Lonza Biosciences) were subjected to Transwell chondrogenic differentiation as described by
Murdoch et al. [34] and Barter et al. [35]. Cartilage discs were harvested after 3, 7 and 14 days
and RNA extracted from the ground tissue using the Trizol/chloroformmethod (Invitrogen).
cDNA was synthesised as for cartilage samples and subjected to qRT-PCR, as above.
Results
The OA Susceptibility Maps to a Conserved Region Predicted to Act as
an Enhancer
In order to determine the size of the OA susceptibility region marked by rs835487, we used
LDlink [12], which utilises genotype data of 503 Europeans generated by the 1000 Genomes
Project [13], to identify SNPs in high LD with rs835487. This identified six additional SNPs in
the European (EUR) population (the population used in the arcOGEN study) with an r2 0.8
with rs835487; all seven SNPs are located within a 2726 bp region of intron 2 of CHST11 (chro-
mosome 12:105059930–105062656), approximately 210 kb downstream of the transcription
start site of the gene (Fig 1A and 1B). This region is flanked by two recombination hotspots
located at approximately chromosome 12:105059400 and chromosome 12:105063200 (a 3800
bp region), with LD tailing off either side of these hotspots; the SNP with the highest LD with
rs835487 outside of the LD block has an r2 of only 0.624 and was genotyped in the arcOGEN
study, with a less significant p-value. Together, this indicates that one or more of the seven
SNPs within the 2.7 kb block mediate the OA association signal marked by rs835487.
Analysis of publically available ENCODE datasets on the UCSC genome browser [24] indi-
cates that the LD region contains several DNaseI hypersensitivity sites (DHSs) and transcrip-
tion factor binding sites (Fig 1A) that overlap several of the seven SNPs, and has a chromatin
signature indicative of enhancer activity in several transformed human cell lines. Furthermore,
analysis of chromatin data from the RoadMap Epigenome Project [25] reveals that this region
is also predicted to act as an enhancer in bone marrow derived mesenchymal stem cells
(BM-MSCs), in in vitro differentiated chondrocytes and in primary osteoblasts. Examination
of the Promoter Enhancer Slide Selection Tool (PrESSto) database [26] reveals that the LD
block produces small bidirectional capped transcripts, a signature of active enhancers, in sev-
eral human cells and tissues. The region is conserved in eutherian mammals, although it has
diverged in the lagomorpha and rodentia lineages (S2 Table, S1 and S2 Figs). ClustalW
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Fig 1. The OA risk locus at chromosome 12q23maps to a predicted enhancer element. (A) UCSC genome
browser view of the OA locus with the DNase1 Hypersensitivity, Transcription Factor ChIP-seq, and chromatin
state segmentation tracks from the ENCODE project [24], the chromatin state tracks for bone-marrow derived
mesenchymal stem cells (BM-MSCs), in vitro differentiated chondrocytes and primary osteoblasts from the
RoadMap Epigenome project [25], enhancer transcripts from the FANTOM 5 consortium [26] and the SNP track
containing data from dbSNP 138. For the SNP track (“Simple Nucleotide Polymorphisms (dbSNP 138) Found in
> = 1% of Samples”), the seven vertical lines mark the positions of, from left to right, rs835486, rs835487,
rs835488, rs835490, rs835491, rs835492 and rs835493. rs835487marks the OA association residing at this
locus, with the other six SNPs having a pair-wise r2 of > 0.8 with rs835487. The positions of the regions cloned
into the pGL3 promoter vector for luciferase studies (Fig 2 and S3 Fig) are indicated by rectangles. (B) Table of
the seven SNPs within the enhancer region marked by rs835487. The alleles of each SNP are listed, with the OA-
associated allele highlighted in bold, and the r2 and Dʹ to rs835487 in the European population given for the other
six SNPs within this LD block. PICS score (probabilistic identification of causal SNPs) is a probability estimate that
the SNP is the causal variant [14]; in an LD block the total PICS score will be 1 with SNPs in highest LD with the
association SNP having larger PICS scores.
doi:10.1371/journal.pone.0159024.g001
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alignments of the 60 bp region surrounding each of the seven SNPs in the 42 mammalian spe-
cies listed in S2 Table, revealed that the rs835487 SNP is the most conserved (that is, the region
surrounding rs835487 is present in the largest number of species), with the rs835486 SNP
region only being present in higher primates (S1 Fig). For rs835487, rs835488 and rs835492,
the OA allele is the ancestral allele in mammals and is the major allele within the African
(AFR) population, with the newly evolved non-OA allele being the major allele in non-AFR
populations [13]. The increased frequency of the non-OA alleles at these SNPs in non-Africans
suggests that these alleles may have undergone positive selection, although random genetic
drift may also be responsible. Furthermore, using the probabilistic identification of causal
SNPs (PICS) algorithm [14], rs835487 is predicted to be the causal OA SNP (Fig 1B).
The mouse and rat orthologues of CHST11 contain several enhancers, which together form a
super-enhancer in proliferating and prehypertrophic chondrocytes of both mesodermal and neu-
ral crest origin [15,16]. The Chst11 super-enhancer is bound by the key chondrogenic transcrip-
tion factor SOX9 in mouse chondrocytes and by the SOX9/SOX5/SOX6 trio in rat chondrocytes.
Binding of the SOX trio to the Chst11 super-enhancer is thought to regulate expression of this
gene in chondrocytes; overexpression of SOX9 leads to a ~2 fold upregulation in CHST11 expres-
sion in human dermal fibroblasts [15], whilst expression of Chst11 is abolished in mouse growth
plate chondrocytes lacking Sox9 or Sox5/Sox6 [16]. Although there is significant sequence diver-
gence between humans and rodents, one of the rodent enhancers within the Chst11 chondrocyte
super-enhancer maps to a region orthologous to the human OA LD region (S2 Fig). Within this
homologous region, the highest conservation between the human, rat and mouse sequences
occur at regions bound by SOX9 and SOX5/SOX6 and these conserved regions are also positive
for the poised and active enhancer marks H3K27Ac and H3K4me1 in E14.5 mouse limbs.
Together, these observations suggest that the OA susceptibility region acts as a conserved
distal enhancer of gene expression.
The OA Region Regulates Promoter Activity, With the Alleles of
rs835487 and rs835488 Having Differential Effects
The divergence in nucleotide sequence between humans and rodents, particularly around the
SNP regions, precludes direct analysis of the associated region in commonly used animal mod-
els, such as mice. Our functional analysis therefore focussed on human cells. To confirm that
the OA susceptibility region acts as an enhancer and to identify which of the seven SNPs is the
causal SNP(s), we performed in vitro luciferase enhancer assays in SW1353 human chondro-
sarcoma and MDA-MB-231 human adenocarcinoma cell lines. The enhancer region was
cloned as two separate fragments into the pGL3 luciferase vector upstream of a minimal pro-
moter, with the first fragment containing three SNPs (rs835486-rs835487-rs835488) and the
second fragment four SNPs (rs835490-rs835491-rs835492-rs835493).
There was significantly higher enhancer activity of the OA-associated minor GGT haplotype
of rs835486-rs835487-rs835488 compared to the non-OA AAC haplotype in SW1353 chondro-
sarcoma (1.96 fold, p< 0.001; Fig 2A) andMDA-MB-231 adenocarcinoma cells (1.95 fold,
p< 0.001; S3A Fig). In SW1353 cells, both haplotypes of this region acted as an enhancer, with
higher luciferase activity than the basal empty pGL3 promoter control vector, but in MDA-MB-
231 cells, the AAC haplotype acted as a repressor, suggesting the regulatory effect of this region
on promoter activity depends on the cellular context. The rs835490-rs835491-rs835492-rs835493
region acted as an enhancer in SW1353 cells but not inMDA-MB-231 cells (Fig 2A and S3B Fig).
No significant difference in promoter activity was observed in either cell line between the CCAC
and OA-associated TTGT haplotypes for the rs835490-rs835491-rs835492-rs835493 fragment,
suggesting the OA susceptibility SNP does not reside in this region.
Functional Analysis of OA Genetic Susceptibility
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To identify which of the SNPs within the rs835486-rs835487-rs835488 region is the causal
SNP, site directed mutagenesis was used to introduce the OA-associated allele of each SNP indi-
vidually into the non-OA AAC haplotype. Introduction of the OA-associated G allele of rs835486
had no effect on enhancer activity of the rs835486-rs835487-rs835488 region in either cell line
(Fig 2B and S3C Fig). However, there was significantly higher enhancer activity after introduction
of the OA-associated G allele of rs835487 in both SW1353 cells (1.72 fold, p< 0.001; Fig 2B) and
MDA-MB-231 cells (1.73 fold, p< 0.001; S3C Fig). Introduction of the OA-associated T allele of
rs835488 to create the AAT haplotype of rs835486-rs835487-rs835488 also increased enhancer
activity by 1.95 fold in SW1353 cells (p< 0.001, Fig 1B) and 2.24 fold inMDA-MB-231 cells
(p< 0.001, S3C Fig) relative to the AAC haplotype created by the C allele of rs835488. This data
suggests that both rs835487 and rs835488 contribute to the haplotype differences in enhancer
activity of this region. This was confirmed by cloning all three SNPs within the rs835486-rs835
487-rs835488 region separately. As expected, no allelic differences in activity were observed for
the rs835486 SNP (Fig 2C). However, there was significantly increased activity of the OA risk
alleles of both rs835487 and rs835488 relative to the non-OA allele of these SNPs in both cell
Fig 2. The OA risk locus has haplotype-specific differences in luciferase reporter activity. (A) To (C)
luciferase enhancer assays in the SW1353 human chondrosarcoma cell line using the pGL3 promoter
plasmids. The vectors were co-transfected with the pRL-TK Renilla plasmid, and luciferase/renilla values
normalised to the empty pGL3-enhancer vector. (A) Luciferase activity of the major AAC and OA-associated
GGT haplotype of the region containing the rs835486, rs835487 and rs835488 SNPs and luciferase activity
of the CCAC and OA-associated TTGT haplotype of the region containing rs835490, rs835491, rs835492
and rs835493. (B) Luciferase activity of the rs835486-rs835487-rs835488 vectors containing the AAC, GAC,
AGC and AAT haplotypes. Mutating the non-OA allele into the OA-risk allele of rs835486, rs835487 or
rs835488, respectively, created the GAC, AGC and AAT vectors. (C) Luciferase activity of the rs835486
region (left), rs835487 region (middle) or rs835488 region (right). Data shown is the mean ± standard error of
at least four independent experiments, each with five technical repeats. ***p < 0.001, Mann-Whitney U test.
N/S, not significant. The data points that enabled construction of this figure can be found in S5 Table.
doi:10.1371/journal.pone.0159024.g002
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lines (Fig 2C and S3D Fig). These two SNPs have a pairwise r2 of 0.962 in the European popula-
tion and create two common haplotypes, AC and the OA-associated GT, which have a frequency
of 0.633 and 0.358 respectively. Together, the luciferase data suggests that the OA region acts as a
cis-acting regulator of gene expression, with the OA susceptibility residing at this locus poten-
tially caused by the combined effects of allelic differences in regulatory activity of the rs835487
and rs835488 SNPs.
Differential transcription factor binding to rs835487 and rs835488 Alleles
The allelic differences in enhancer activity of rs835487 and rs835488 are likely to be caused by
differences in protein binding and this was investigated using electrophoretic mobility shift
assays (EMSAs). EMSAs were performed using nuclear extracts with double-stranded labelled
DNA probes for both alleles of each SNP (Fig 3A, Fig 4A, S4A and S4C Fig).
Several protein complexes were found to bind to both alleles of rs835487 in SW1353 (Fig 3B,
upper bands) andMDA-MB-231 (S4B Fig, upper bands) nuclear lysates, with an additional
complex binding specifically to the A allele (Fig 3B and S4B Fig, lower band). For the upper com-
plexes, protein binding was outcompeted at a lower concentration of unlabelled G allele competi-
tor than the A allele competitor, indicating that these proteins bind more avidly to the OA risk G
Fig 3. The OA-associated allele of rs835487 has increased binding of nuclear protein complexes containing
SP1, SP3 and SUB1. (A) Positive strand sequence of the rs835487 double-stranded EMSA DNA probes with the
alleles of the SNP highlighted in bold. (B) EMSA with rs835487 A and G allele probes with and without unlabelled A
and G allele competitors. Unlabelled competitors were present in 0-, 10-, 25-, 50- and 100-fold molar excess as
indicated and arrows denote rs835487-protein complexes. (C) EMSA using a competitor containing the SP1/SP3
consensus sequence. Arrows indicate the DNA-protein complexes that are reduced upon addition of the SP1/SP3
competitor. (D) Supershift of the rs835487-protein complexes with antibodies against SP1, SP3 and SUB1. Arrows
denote the complexes that are supershifted with the antibody. Nuclear extracts from SW1353 human chondrosarcoma
cell line were used in all EMSAs. Ab, antibody.
doi:10.1371/journal.pone.0159024.g003
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allele. Using the online databases matInspector, Promo3.0, TESS and TFSEARCH, we identified
several transcription factors that were predicted to bind over rs835487 (S3 Table). Competition
assays with competitors containing the consensus-binding site of these proteins and supershift
assays using antibodies against these proteins were then performed (Fig 3C and 3D, and S5A
Fig). Addition of SP1/SP3 competitors containing the consensus sequence GGGGGCG GGGG
(Fig 3C) reduced the upper three protein-probe complexes in a concentration dependent man-
ner, suggesting that SP1 and/or SP3 is a component of these complexes. None of the transcription
factor consensus sequences outcompeted binding of the A-specific protein (data not shown). The
upper rs835487-protein complex outcompeted with the SP1/SP3 consensus sequence was super-
shifted upon addition of an anti-SP1 antibody (Fig 3D, left panel), while the lower two complexes
were supershifted with an anti-SP3 antibody (Fig 3D, middle panel), confirming that SP1 and SP3
bind over the rs835487 SNP in vitro. We have previously reported that the transcriptional co-acti-
vator protein SUB1 forms a complex with SP1 and SP3 [17] so we examined whether SUB1 also
binds over the rs835487 SNP. Addition of an anti-SUB1 antibody reduced the formation of the
SP1 containing complex and the upper SP3 containing complex (Fig 3D, right panel), but had lit-
tle or no effect on the lower SP3-containing complex, suggesting that SUB1 stabilises the upper
two complexes but not the smallest SP3 complex. Experiments with antibodies against other tran-
scription factors did not supershift any of the rs835487 complexes, implying that it was not the
presence of an antibody per se that created a shift but the presence of antibodies targeting SP1,
SP3 and SUB1 (S5A Fig).
Several protein complexes were identified that bind to both alleles of the rs835488 SNP (Fig
4B and S4D Fig). These complexes bind more avidly to the OA risk T allele, with a lower con-
centration of the unlabelled C and T allele competitors required to outcompete the C allele
complexes than the T allele complexes. Several transcription factors were predicted to bind to
rs835488 (S3 Table) but only competitors for and antibodies against SP1 and SP3 reduced for-
mation of the rs835488-protein complexes (Fig 4C and 4D). Addition of an anti-SP1 antibody
reduced the formation of the largest rs835488-protein complex (Fig 4D, far left panel) and the
formation of three complexes were reduced upon addition of an anti-SP3 antibody (Fig 4D,
centre left panel). The region surrounding rs835488 (AGGCC/TGTCTC) is similar to the YY1
consensus sequence VDCCATNWY [27], and this transcription factor is known to form tran-
scription complexes with both SP1 and SP3. We therefore investigated whether YY1 binds over
rs835488. Addition of an anti-YY1 antibody reduced the formation of all three SP3-containing
complexes (Fig 4D, centre right panel), suggesting that these complexes contain both SP3 and
YY1. Formation of the SP1 and SP3-YY1 complexes was reduced in the presence of an anti-
body against SUB1 (Fig 4D, far right panel), indicating that SUB1 stabilises the formation of
the rs835488 protein complexes. As for rs835487, shifts were not observed when antibodies tar-
geting other trans-acting factors were used (S5B Fig).
In summary, the EMSA data highlighted allelic differences in protein binding to both
rs835487 and rs835488 and identify SP1, SP3, YY1 or SUB1 as transcription factors differen-
tially binding to this OA susceptibility locus.
CHST11 as a Potential Target for the OA Susceptibility
The above data suggests (but does not definitively prove) that 1) the OA association region acts
as a distal regulator of gene expression, and 2) that the susceptibility mediated by this region
functions through causing allelic differences in target gene expression due to differential pro-
tein binding to the rs835487 and rs835488 SNPs. The majority of enhancer-promoter interac-
tions occur between elements located on the same chromosome (in cis interactions) rather
than between elements on different chromosomes (in trans interactions). Studies of chromatin
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interactions in human cells using high resolution chromosome conformation capture technol-
ogies have demonstrated that most in cis interactions occur between elements within the same
topological domain [28]. These topological domains have a median size of 1 Mb in humans,
and the topological domain containing the rs835487-rs835488 region is located between chro-
mosome 12:104,120,000–105,120,000 in the H1 human ES cell line and between chromosome
12:104,320,000–105,240,000 in the human IMR90 fibroblast cell line (http://chromosome.sdsc.
edu/mouse/hi-c/download.html; [28]). To discover the putative target gene of the rs835487-
rs835488 enhancer region, we concentrated on genes whose transcription start sites (TSS) were
located within the rs835487-rs835488 topological domain. As the borders of this topological
domain vary between cell types, we analysed the region located between 1 Mb up and down-
stream of the OA susceptibility region, that is the region on chromosome 12 between 104,059,
920 and 106,062,650. This region contained the TSS of 18 genes and 1 pseudogene, which are
listed in S4 Table. A literature search of these 18 genes identified CHST11 as the most likely
candidate gene of the rs835487-rs835488 enhancer based on the following observations: A) the
orthologous region in rodents is part of a super-enhancer that regulates Chst11 expression in
proliferating and prehypertrophic chondrocytes ([15,16]; S2 Fig); B) according to the Hap-
loReg V4 database, rs835487 acts as a CHST11 expression quantitative trait locus (eQTL), albeit
in cerebellum and temporal cortex [29,30]; C) mice lacking CHST11 protein have severe
Fig 4. The OA-associated allele rs835488 has increased binding of nuclear protein complexes containing SP1,
SP3, YY1 and SUB1. (A) Positive strand sequence of the rs835488 probes with the alleles of the SNP highlighted in
bold. (B) rs835488 EMSA with the C and T allele probes with 0-, 10-, 25-, 50- and 100-fold molar excess of unlabelled C
and T allele competitors; the rs835488-protein complexes are indicated by arrows. (C) rs835488 EMSA with SP1/SP3
consensus sequence competitors; DNA-protein complexes outcompeted by SP1/SP3 competitors are denoted by
arrows. (D) Addition of antibodies against SP1, SP3, YY1 and SUB1 reduce formation of specific rs835488-protein
complexes, as indicated by arrows. Nuclear extracts from SW1353 human chondrosarcoma cell line were used in all
EMSAs. Ab, antibody.
doi:10.1371/journal.pone.0159024.g004
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chondrodysplasia, indicating Chst11 is required for normal skeletogenesis [31]; D) CHST11
sulfates chondroitin to produce chondroitin sulfate, a key component of cartilage proteoglycan
that is crucial for extracellular matrix interactions with growth factors and other signalling
molecules [7]; E) CHST11 is differentially methylated in OA cartilage relative to non-OA carti-
lage [32]; and F) CHST11 expression is upregulated in cartilage from patients with OA [33].
We therefore focussed on this gene.
We measured the expression of CHST11 in cartilage from patients who had undergone joint
replacement surgery either due to primary hip OA (n = 22) or primary knee OA (n = 40), or
due to neck of femur (NOF) fracture (n = 19). CHST11 was upregulated approximately 2.7 fold
in OA hip and OA knee cartilage relative to non-OA hip cartilage from the NOF individuals
(p< 0.001, Fig 5A).
Given our hypothesis that the rs835487-rs835488 region acts as an enhancer, and that there
are allelic differences in enhancer activity in vitro, we stratified our OA hip and OA knee carti-
lage CHST11 expression data by genotype at rs835487 to determine if the rs835487-rs835488
Fig 5. CHST11 expression in adult cartilage and during chondrogenesis. (A)CHST11 expression in
cartilage samples from neck of femur (NOF) fracture patients, OA hip and OA knee patients. (B)CHST11
expression in OA hip and OA knee cartilage stratified by genotype at the OASNP rs835487. (C) Allelic
expression imbalance (AEI) of theCHST11 transcript SNP rs2463018 stratified by genotype at rs835487 in
NOF, OA hip and OA knee cartilage. Although only rs835487 genotypes are shown, rs835487 and rs835488
had an r2 of 1 in these 66 individuals, with the AA, AG and GG genotypes at rs835487 being in complete LD
with the CC, CT and TT genotypes at rs835488 respectively; rs835487 and rs835488 genotypes are therefore
directly interchangeable in this data set. rs2463018 mRNA allelic ratios were normalised to cartilage DNA from
the same individual. The schematic diagram below the chart indicates the different haplotype combinations of
rs835487 (open box) and rs2463018 (black rectangle). For (A), (B) and (C), each circle, square and triangle
represents data from a single individual. (D) Expression ofCHST11 during in vitro chondrogenic differentiation
of MSCs (3 donors). For (A), (B) and (D),CHST11 expression was normalised to the housekeepers 18s,
GAPDH andHPRT1, and the mean ± standard error is indicated by the error bars. *p < 0.05, **p < 0.01,
***p < 0.001, Mann-WhitneyU test. The data points that enabled construction of panel D of this figure can be
found in S5 Table.
doi:10.1371/journal.pone.0159024.g005
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region acts as an eQTL on this gene. We observed no correlation between rs835487 genotype
and overall CHST11 expression in cartilage when OA samples were combined (Fig 5B) or,
given that the association marked by rs835487 is specific to hip OA, when the data was strati-
fied by joint site (S6A–S6C Fig). The effect of rs835487 genotype on CHST11 expression may
be overshadowed or even hidden by the large inter-individual variability in expression levels,
especially as the so far characterised OA SNP eQTLs have small, subtle effects on gene expres-
sion [9–11]. We therefore investigated potential effects of rs835487 and rs835488 genotype on
CHST11 expression further using allelic expression imbalance (AEI) analysis; this technique
measures the transcriptional output of each allele of a SNP in heterozygous individuals and
therefore is not affected by variability in gene expression between individuals. As the OA sus-
ceptibility SNPs are intronic, we used the CHST11 3'UTR transcript SNP rs2463018 as a proxy;
although this SNP has an r2< 0.001 with rs835487, it has a heterozygous frequency of 41%,
meaning that a large proportion of individuals would be eligible for analysis. We analysed AEI
in cartilage from 66 individuals heterozygous for the rs2463018 transcript SNP. Our genotyp-
ing of these samples revealed that rs835487 and rs835488 were in perfect LD (r2 = 1), with indi-
viduals with the AA, AG and GG genotypes at rs835487 having the CC, CT and TT genotypes
at rs835488 respectively. Twenty-two of the 66 individuals were homozygous for the non-OA
A allele of rs835487, 29 were heterozygous for rs835487 and 15 were homozygous for the OA-
associated G allele of rs835487. Although AEI was observed at rs2463018 in cartilage, the level
and direction of AEI did not correlate with genotype at rs835487 (and therefore not at
rs835488 either) (Fig 5C). Given that the rs835487 OA association is specific to hip OA, we fur-
ther stratified the data based on cartilage joint of origin (S6D–S6F Fig), but found no evidence
that rs2463018 AEI is driven by rs835487 or rs835488 genotype.
Our expression data does not support the OA association signal as acting as an eQTL on
CHST11 in the adult cartilage that we investigated. In mice, Chst11 is expressed in growth plate
chondrocytes, where the protein is required for normal growth plate patterning [31]. To assess
if CHST11 is also expressed in human chondrocytes during chondrogenesis, we in vitro differ-
entiated human iliac crest derived mesenchymal stem cells (MSCs) using the Transwell chon-
drogenic differentiation model [34,35]. CHST11 was expressed in undifferentiated (day 0)
MSCs, and was upregulated approximately three-fold during the first 7 days of chondrogenesis
(p = 0.0021; Fig 5D), when the cells are proliferating. CHST11 levels fell 2-fold between day 7
and day 14 (p = 0.0126) by which time the chondrocytes have stopped proliferating and express
the hypertrophic marker COL10A1 [34,35].
Discussion
Our analysis revealed that rs835487 and rs835488 are the most likely candidate SNPs for the
OA susceptibility that resides at chromosome 12q23 and within intron 2 of CHST11, with their
disease associated GT haplotype having significantly different in vitro enhancer activity relative
to the AC haplotype. However, when we examined the expression of CHST11 in the cartilage
of OA patients, we did not detect a correlation between expression and genotype, even when
using the sensitive AEI approach. However, due to the absence of CHST11 transcript SNPs in
high LD with rs835487, we had to use a transcript SNP not in LD with rs835487 for AEI, limit-
ing the resolution of the assay. Given that most regulatory SNPs have only subtle effects on
their target gene expression, we cannot rule out the possibility that other SNPs in higher LD to
the transcript SNP may have masked the effects of an rs835487 AEI on CHST11 expression in
this assay. Nevertheless, we found no evidence that rs835487 acts as a CHST11 cartilage eQTL
and one explanation for this could be that CHST11 is not the target of the OA susceptibility.
This is of course perfectly possible, although the orthologous enhancer regions in mice and rats
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are part of a super-enhancer that regulates Chst11 in proliferating and prehypertrophic chon-
drocytes [15,16] and rs835487 is associated with a CHST11 eQTL in cerebellum and temporal
cortex [29,30]. It may be therefore that, like many enhancers, the gene regulatory activity of the
OA LD region is temporally and spatially restricted rather than being active throughout the
life-course and would not therefore have been detectable in our analysis of cartilage from
elderly patients.
CHST11 is a very compelling functional candidate based on the known role of its encoded
protein, carbohydrate sulfotransferase 11, on cartilage extracellular matrix biosynthesis. This
enzyme sulfates the glycosaminoglycan (GAG) chondroitin sulfate (CS) [7]. GAGs are chains
of disaccharides that bind to a core protein to form proteoglycan [36]. Alongside collagens,
proteoglycans are the most abundant components of the cartilage extracellular matrix (ECM),
with the principal cartilage proteoglycan being aggrecan. The high sulfate content adds nega-
tive charge to the proteoglycan, which contributes to the water binding capacity of the mole-
cule. In the case of aggrecan and cartilage, this leads to the swelling observed in the healthy
tissue that enables the cartilage to resist load. Sulfation also mediates interaction of the proteo-
glycan with extracellular molecules, including growth factors and cytokines [36]. Aberrant
GAG sulfation can lead to a range of skeletal pathologies, including abnormal growth plate
development, bone shortening and chondrodysplasia [37–39]. Inactivation of the mouse
homolog of CHST11 leads to an imbalance of chondroitin sulfation and loss of cartilage integ-
rity [31].
If CHST11 is the target of the OA susceptibility we therefore speculate that this reflects
usage of the intron 2 enhancer during cartilage development rather than in the adult cartilage
that we investigated. Many enhancers have been reported to act in a specific-cell type and at
a specific developmental stage. For example, a conserved enhancer region within the BCL11A
gene, which acts as a negative regulator of foetal haemoglobin levels, acts as an enhancer of
this gene specifically in the erythroblast cells, and not in B lymphocytes, even though
BCL11A is expressed 10-fold higher in B lymphocytes than erythroblasts [40]. Furthermore,
the enhancer drives expression of BCL11A in fetal liver cells, the site of erythropoiesis, in a
developmentally-specific pattern. Many enhancers that regulate chondrogenic gene expres-
sion during skeletogenesis are also temporally and spatially restricted, including those of
Sox9 [41] and Acan [42]. Several OA genetic susceptibility loci map near to or encompass
genes that play important roles during skeletogenesis [5] and it has been hypothesised that
OA loci do act during joint development by causing subtle alterations in joint architecture
and/or cartilage/bone composition that predispose the individual to OA development later in
life [43,44]. As already noted, Chst11 is expressed in the developing limb during mouse
embryonic skeletogenesis, including in proliferating and pre-hypertrophic but not hypertro-
phic growth plate chondrocytes [7,16,31]. Although it is not possible to look at CHST11
expression during human skeletal development, we did observe dynamic expression of this
gene during in vitro chondrogenesis of human MSCs, with CHST11 expression peaking at
the end of the proliferative phase. Therefore, we suggest that CHST11 could be a further
example of an OA genetic susceptibility that mediates its effect during development of the
joint. To assess if this is the case, the enhancer marked by rs835487 and rs835488 could be
deleted in MSCs by, for example, the use of CRISPR-Cas [45] and the effect that this has on
chondrogenesis and CHST11 expression directly assessed. If no effect on CHST11 expression
were observed but there was an effect on chondrogenesis, then a reasonable conclusion
would be that CHST11 is not the target and as such an expression analysis of all other genes
from within the rs835487-rs835488 topological domain would be merited, in both the dele-
tion model and patient cartilage.
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Conclusions
The OA susceptibility residing within CHST11 is mediated by differential protein binding to
the alleles of rs835487 and rs835488, which are located within a region that functions as an
enhancer of transcription. SP1, SP3, YY1 and SUB1 are the transcription factors whose binding
to the enhancer are altered by the OA associated SNPs.
Supporting Information
S1 Fig. ClustalW alignments of the SNPs within the enhancer region that have an r2 of 0.8
or above with the rs835487 SNP that marks the OA association at this locus. In mammalian
species that have homologous regions to the human LD block within the orthologous CHST11
gene, the 60 bp regions surrounding each of the seven SNPs within the OA signal (rs835486,
rs835487, rs835488, rs835490, rs835491, rs835492 and rs835493) were aligned using ClustalW.
Each SNP is highlighted in yellow. Primate sequences are in black, Cetartiodactyla in blue, Pris-
sodactyla in red, Carnivora in green, Chiroptera in orange, and Afrotheria in purple. rs835486
is only present in primates, with the A allele being ancestral. The region containing rs835487 is
conserved in the largest number of mammalian species (n = 25). The rs835488 region is con-
served in the second largest number of mammalian species (n = 21), with the OA–associated T
allele appearing to be the ancestral allele. In the primate lineage, there are insertions upstream
of rs835490 and rs835491, which may potentially introduce or delete transcription factor bind-
ing sites that are conserved in the other mammalian species.
(PDF)
S2 Fig. The LD region shares homology with an enhancer that regulates Chst11 expression
in rat and mouse proliferating chondrocytes. (A) UCSC genome browser view of the LD
block and surrounding region. The LD block was defined as the region containing SNPs with
r2 of 0.8 or greater with the OA SNP rs835487 within the EUR population and is indicated by
the red rectangle. The black rectangles indicate the regions with homology to the SOX9 and
SOX5/6 ChIPseq peaks present in rat proliferating/early prehypertrophic growth plate chon-
drocytes (RCS tracks; Liu and Lefebvre 2015 [16]), the SOX9 ChIPseq peaks in proliferative
and prehypertrophic rib chondrocytes from postnatal day 1 mice (Mm P1 rib SOX9; [15]), and
the H3K4me1 and H3K27Ac ChIPseq peaks from E14.5 mouse limb (Mm limb H3K4me and
Mm limb H3K27Ac respectively). Homologous regions were identified using the UCSC Lift-
Over tool between the rat RGSC 5.0/rn5, the mouse NCBI37/mm9 and the human GRCh37/
hg19 assemblies. The filled black rectangles within the homologous blocks represent the
regions with over 70% identity between the human and rat/mouse nucleotide sequences; these
regions were identified using the blastn sequence alignment tool that is optimised for ‘some-
what similar sequences’. The chromatin state segmentation tracks for human bone-marrow
derived mesenchymal stem cells (Hs BM-MSC), in vitro differentiated chondrocytes (Hs Chon-
drocytes) and primary osteoblasts (Hs osteoblasts) from the RoadMap Epigenome project,
human transcription factor binding sites (Hs TF ChIP-seq) and DnaseI hypersensitivity sites
(Hs DHS clusters) from the ENCODE project, and human enhancer transcripts from the FAN-
TOM 5 consortium (Hs transcribed enhancer; [26]) are also indicated. The seven vertical lines
mark the positions of, from left to right, rs835486, rs835487, rs835488, rs835490, rs835491,
rs835492 and rs835493 (OA SNPs). (B) Alignment of the LD region in 29 mammalian species
generated using the Multiz tool in UCSC.
(PDF)
S3 Fig. The OA risk locus has haplotype-specific differences in luciferase reporter activity.
(A) to (D) Luciferase enhancer assays in the MDA-MB-231 human adenocarcinoma cell line
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using the pGL3 promoter plasmids. The vectors were co-transfected with the pRL-TK Renilla
plasmid, and luciferase/renilla values normalised to the empty pGL3-enhancer vector. (A)
Luciferase activity of the AAC and OA-associated GGT haplotype of the region containing the
rs835486, rs835487 and rs835488 SNPs. (B) Luciferase activity of the CCAC and OA risk
TTGT haplotype of the region containing rs835490, rs835491, rs835492 and rs835493. (C)
Luciferase activity of the rs835486-rs835487-rs835488 vectors containing the AAC, GAC,
AGC and AAT haplotypes. Mutating the non-OA allele into the OA-risk allele of rs835486,
rs835487 or rs835488, respectively, created the GAC, AGC and AAT vectors. (D) Luciferase
activity of the two alleles of rs835487 only (left) or rs835488 only (right). There is increased
luciferase activity of the OA associated alleles of both SNPs. Data shown is the mean ± standard
error of at least four independent experiments, each with five technical repeats. p< 0.05,
p< 0.001, Mann-Whitney U test. N/S, not significant. The data points that enabled con-
struction of this figure can be found in S5 Table.
(PDF)
S4 Fig. rs835487 and rs835488 competiton EMSAs with MDA-MB-231 protein lysates. (A)
Positive strand sequence of the rs835487 double-stranded EMSA DNA probes with the alleles of
the SNP highlighted in bold. (B) MDA-MB-231 nuclear lysate EMSA with rs835487 A and G
allele probes with and without unlabelled A and G allele competitors. Unlabelled competitors
were present in 0-, 10-, 25-, 50- and 100-fold molar excess as indicated and arrows denote rs835
487-protein complexes. (C) Positive strand sequence of the rs835488 probes with the alleles of
the SNP highlighted in bold. (D) rs835488 EMSA with the C and T allele probes with 0-, 10-, 25-,
50- and 100-fold molar excess of unlabelled C and T allele competitors andMDA-MB-231
nuclear proteins.
(PDF)
S5 Fig. Supershift assays for the rs835487 and rs835488 protein complexes. (A) rs835487 A
allele gel supershift assays with antibodies against 17 transcription factors. The rs835487-pro-
tein complexes are only supershifted upon addition of antibodies against SP1 or SP3, with no
supershifts observed for the other 15 antibodies tested. The SP1-containing complexes are indi-
cated by the long arrows, with the short arrow indicating SP3-containing complexes. (B)
rs835488 C allele supershift assays with antibodies against 16 transcription factors. Addition of
an anti-SP1 antibody reduces formation one of the rs835488-protein complexes (long arrow),
and formation of two complexes are decreased upon the addition of anti-SP3 or anti-YY1 anti-
bodies (short arrows). An anti-SUB1 antibody reduces formation of all three SP1/SP3/YY1
containing complexes. Nuclear extracts from SW1353 human chondrosarcoma cell line were
used in all EMSAs. Ab, antibody. Ctl Ab, anti-PAX6 polyclonal antibody used as an IgG con-
trol.
(PDF)
S6 Fig. Association analysis of CHST11 expression with rs835487 genotype. (A) to (C)
CHST11 expression in (A) neck of femur (NOF) fracture, (B) OA hip and (C) OA knee carti-
lage stratified by genotype at the OA-associated SNP rs835487. Expression was measured by
qRT-PCR and normalised to the housekeeping genes 18s, HPRT1 and GAPDH. The error bars
indicate the mean ± standard error. Due to the low number of GG homozygotes in the OA hip
analysis, the heterozygotes and GG homozygotes were combined as G carriers and compared
to the AA homozygotes. (D) to (F) Allelic expression imbalance (AEI) of the CHST11 tran-
script SNP rs2463018 stratified by genotype at the OA SNP rs835487 in (D) NOF, (E) OA hip
and (F) OA knee cartilage. Although only rs835487 genotypes are shown, rs835487 and
rs835488 had an r2 of 1 in these 66 individuals, with the AA, AG and GG genotypes at
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rs835487 being in complete LD with the CC, CT and TT genotypes at rs835488 respectively;
rs835487 and rs835488 genotypes are therefore directly interchangeable in this data set. Allelic
ratios were normalised to cartilage DNA from the same individual. For (A) to (F), each circle,
square and triangle represents data from a single individual.
(PDF)
S1 Table. A list of primers used in this study. The bold and underlined nucleotides in the Site
directed mutagenesis primers are the mutagenized SNP alleles; the bold and underlined nucleo-
tides in the EMSA probes are the SNP sites; the underlined sequences in the SP1/SP3 primers
is the consensus sequence for the transcription factors.
(PDF)
S2 Table. Conservation of the OA-associated enhancer region in mammals. The OA associ-
ated region maps to chromosome 12 within intron 2 of the CHST11 gene at hg19:105,059,911–
105,062,613 and contains seven SNPs in high LD (r2> 0.8). To identify homologous enhancer
regions in other mammalian species, the 2.7 kb genomic region encompassing the human OA
locus was aligned against the genomes of other mammals using the UCSC BLAT software. The
homologous sequences from species where the enhancer was conserved within intron 2 of
CHST11 were aligned using ClustalW software. The OA enhancer region is present in euthe-
rian mammals, but not in monotremes or marsupials. The enhancer region has diverged in the
Rodentia and Lagomorpha lineages, with some regions being absent. The allele present in the
reference genome of the different species at each SNP is listed in the table. For humans, the
common non-risk allele is given followed by the minor OA risk allele. Bp del; for rs835487, the
region surrounding the SNP is conserved in elephants although the SNP nucleotide itself has
been deleted. C del; for rs835490, the region 5ʹ to the SNP has either been lost from the Super-
order Laurasiatheria or gained in the primate order. 4bp in; there has been a 4 bp TCAG inser-
tion 2 bp upstream of the rs835491 SNP in the NewWorld primates (in bold) and Squirrel
Monkey genomes and a 4 bp GAAT insertion 5 bp upstream of rs835492 in the Lemur genome.
15bp in; there is a 15 bp insertion 2 bp 5ʹ to the rs835491 SNP in Marmosets.
(PDF)
S3 Table. Transcription factors identified using the online databases matInspector,
Promo3.0, TESS and TFSEARCH as predicted to bind over rs835487 and rs835488. The
consensus and competitor sequences used in the subsequent competition EMSAs are also listed.
(PDF)
S4 Table. Genes with transcription start sites located within the 2Mb region surrounding
rs835487. Details of the gene transcription start site (TSS) and function of the gene/encoded
protein are listed, together with information on whether they demonstrate altered expression
in OA cartilage versus non-OA cartilage (using data from [32]), or whether they show altered
expression in OA cartilage versus non-OA cartilage (using data from [22,33]). Also listed is
whether they have a reported role in the musculoskeletal system based on searches of PubMed
(http://www.ncbi.nlm.nih.gov/pubmed) and OMIM (http://www.ncbi.nlm.nih.gov/omim) and
information from mice deletion models.
(PDF)
S5 Table. The data points used for the construction of Fig 2, S3 Fig and Fig 5D. The first sheet
contains the data points for Fig 2 and the luciferase assay of SW1353 human chondrosarcoma
cells. The second sheet contains the data points for S3 Fig and the luciferase assay of MDA-MB-
231 human adenocarcinoma cells. The third sheet contains the data points for Fig 5D andMSC
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chondrogenesis.
(XLSX)
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